Small logo Subscribe to leading news on impact investing. Learn More
The Brief Originals Dealflow Signals The Impact Alpha Impact Voices Podcasts Agents of Impact Open
What's Next Measure Better Investing in Racial Equity Beyond Trade-offs Impact en las Americas New Revivalists
Local and Inclusive Climate Finance Catalytic Capital Capital on the Frontier Best Practices Geographies
Slack Conference Calls Events Contribute
The Archive ImpactSpace The Accelerator Selection Tool Network Map
About Us FAQ Calendar Pricing and Payment Policy Privacy Policy Terms of Service Agreement Contact Us
Locavesting Entrepreneurship Gender Smart Return on Inclusion Good Jobs Creative economy Opportunity Zones Investing in place Housing New Schooled Well Being People on the Move Faith and investing Inclusive Fintech
Clean Energy Farmer Finance Soil Wealth Conservation Finance Financing Fish
Innovative Finance
Personal Finance Impact Management
Africa Asia Europe Latin America Middle East Oceania/Australia China Canada India United Kingdom United States
Subscribe Log In

Aqua-Spark backs aquaculture ventures Proteon Pharmaceuticals and Cryoocyte

The Dutch aquaculture fund has made 15 sustainable aquaculture investments over the last two years.

Poland-based Proteon has developed an antibiotic-free method of killing bacteria like salmonella in fish and poultry.

Aqua-Spark was the sole investor in its $4.1 million Series A round. “We’ve been looking at disease-battling companies from the beginning,” Aqua-Spark co-founder Mike Velings told AgFunderNews.

Aqua-Spark also co-led (with Vodia Ventures) the $4 million Series A round for Cryoocyte, which is working on technology for freezing fish eggs.

The technology could be important in preserving long-term biodiversity in aquaculture.

You might also like...